[PDF] Top 20 Ansiedad y depresión en padres cuyos hijos presentan quemaduras.
Has 9320 "Ansiedad y depresión en padres cuyos hijos presentan quemaduras." found on our website. Below are the top 20 most common "Ansiedad y depresión en padres cuyos hijos presentan quemaduras.".
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
... in patients with renal impairment the plasma concentration and half-life of the drug are significantly higher ...lower lenalidomide starting doses in this population. A subanalysis of patients from ... See full document
30
Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients
... Abstract: Multiple myeloma (MM) is an incurable hematologic malignancy caused by the autonomous growth of malignant plasma ...and lenalidomide has dramatically improved the clinical outcome of ... See full document
8
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
... A multicenter, open-label, randomized phase II study to evaluate 2 dose regimens of lenalidomide for relapsed, refractory MM has been ...this ... See full document
10
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial
... five patients with plasmacytomas in MM-011 achieved SD following treatment with poma- lidomide plus low-dose dexamethasone, albeit with a short median PFS of ...with MM is ... See full document
5
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study
... Continuation study were lower in both treatment arms than in the global ...that Chinese MM patients present with more advanced- stage disease, renal dysfunction, and bone destruction than ... See full document
8
Novel agents in the treatment of multiple myeloma: a review about the future
... in MM cells, as well as in other hematologic, solid, and neuroendocrine ...and lenalidomide, prompting the design of a phase 1/2a trial investigating ... See full document
14
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma
... To validate our analysis we compared our outcomes with those of existing inter network comparisons (see outcomes summarised in Table 7). While no gold stand- ard exists, two analyses based on individual patient level ... See full document
267
Plitidepsin: design, development, and potential place in therapy
... most common were myalgia, muscle weakness, and increase in serum CPK (noncardiac fraction) levels. Myalgia usu- ally started proximally (shoulders, neck or thighs) at about 3 weeks after treatment onset, whereas muscle ... See full document
8
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
... in MM, and received priority review and orphan drug status in both US and Europe, when used in combination with bortezomib and dexamethasone in the treatment of ...of Phase III data obtained in the ... See full document
13
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
... All patients had previously been exposed to both lenalidomide and bortezomib and received a median of 5 prior antimyeloma treatment ...Pomalidomide plus low-dose dexamethasone ... See full document
117
New developments in the treatment of multiple myeloma – <br />clinical utility of daratumumab
... the approved regimens involving monoclonal antibodies in hematologic malignancies contain cyclophosphamide, such as rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone in B-cell lymphoma and ... See full document
54
Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
... Multiple myeloma (MM) is one of the most common hematologic malignancies, with approximately 86,000 new cases and 63,000 deaths reported globally each year [1], with recent reports suggesting that ... See full document
5
Panobinostat for the treatment of multiple myeloma: the evidence to date
... Abstract: Multiple myeloma is a malignancy involving plasma cell proliferation within the bone ...of patients diagnosed with myeloma has significantly improved in the last decade, following ... See full document
7
Chimeric antigen receptor T cell therapies for multiple myeloma
... treat MM patients. In a phase 1/2 clinical trial of BT062, only 1 out of 23 patients showed an objective clinical response ...with lenalidomide, the overall response rate ... See full document
12
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
... For the co-primary endpoints, we estimated summaries of time to event per treatment group using the Kaplan- Meier method. We made comparisons between the allocated groups using the Cox proportional hazards model ... See full document
205
Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
... Multiple myeloma (MM), the second most common hematologic cancer, is character- ized by uncontrolled clonal proliferation of malignant plasma cells within the bone marrow, with associated monoclonal ... See full document
54
EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
... (RESONATE trial) 31 32 was considered to be low; it was credited for PFS advantage including gain in the tail of the curve but was penalised for toxicity associ- ated with the more prolonged drug exposure ... See full document
6
Follow Up Study of a Multiple Myeloma Patient Successfully Treated with Clarithromycin (CAM), Low Dose Lenalidomide and Low Dose Dexamethasone: Significance and Possible Mechanism of Action of CAM as an Add On Therapy
... ≥110 mm/hr; normal range [nr]. 3 - 15 mm/hr), CRP ...β 2 -microglobulin (8.2 mg/L; nr. 0.9 - 1.9 mg/L), soluble-IL-2 receptors (s-IL-2R) (766 IU/mL; ... See full document
7
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
... immunotherapy. Multiple agents targeting PD1, PD-L1, or CTLA-4 are widely applied as immune checkpoint inhibitors (ICIs) which alleviate the suppression of immune regulatory machineries and lead to immunoablation ... See full document
126
Original Article A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide
... with MM, who developed nasopha- ryngeal carcinoma (NPC), 46 months after the diagnosis of MM and 21 months after the initial lenalidomide ...case study docu- mented the unusual presentation of ... See full document
91
Related subjects